Francesco Latini | White matter | Best Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Francesco Latini | White matter | Best Researcher Award

Assoc. Prof. Dr. Francesco Latini, Uppsala University Hospital, Sweden

Assoc. Prof. Dr. Francesco Latini, M.D., Ph.D., is an Associate Professor in Neurosurgery at Uppsala University Hospital, Sweden. His expertise spans general neurosurgery, neuro-oncology, and cerebrovascular diseases. With a deep interest in brain connectivity and gliomas, Dr. Latini has contributed significantly to advancing neurosurgical practices. He leads the Neurointermediate Intensive Care Unit and coordinates regional clinical processes for malignant brain tumors. 🌍🧠💉

Publication Profile

Google Scholar

Education

Dr. Latini graduated in 2006 from the University of Bologna, Italy. He completed his specialization in Neurosurgery in 2013 (cum laude) at the University of Ferrara, Italy. In 2021, he earned a Ph.D. in Medical Sciences from Uppsala University, focusing on the anatomy and behavior of low-grade gliomas. His training includes specialized fellowships in neurovascular surgery and neuro-oncology at various prestigious institutions worldwide. 🎓📚🏥

Experience

Dr. Latini’s career spans from Resident in Neurosurgery at S.Anna University-Hospital, Ferrara (2008-2013) to roles in Uppsala University-Hospital since 2014. He has held positions as a ward physician, junior consultant, and senior consultant in neurosurgery. Currently, he heads the Neurointermediate Intensive Care Unit and serves as the regional coordinator for malignant brain tumor clinical processes. He is also an associate professor in neurosurgery. 🏥🧑‍⚕️💼

Awards and Honors

Dr. Latini has received numerous awards for his contributions to neurosurgery, including recognition for his work in neuro-oncology and cerebrovascular diseases. He is highly regarded in both research and clinical practice and has been acknowledged for his clinical leadership in brain tumor management and neurosurgical innovation. His honors reflect his excellence in both teaching and surgical practice. 🏆🎖️🌟

Research Focus

Dr. Latini’s research primarily focuses on the role of white matter anatomy in the behavior and surgical treatment of low-grade gliomas. He explores the radiological and histopathological features of diffuse gliomas, aiming to develop new models for their treatment. His work bridges the gap between clinical neurosurgery and advanced imaging technologies, emphasizing preoperative planning and patient outcomes. 🧠🔬

Publication Top Notes

  • Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I–III – Cited by: 118 – Year: 2014 🧠📑

  • Segmentation of the inferior longitudinal fasciculus in the human brain: A white matter dissection and diffusion tensor tractography study – Cited by: 117 – Year: 2017 🧠📊

  • Extension of diffuse low-grade gliomas beyond radiological borders as shown by the coregistration of histopathological and magnetic resonance imaging data – Cited by: 80 – Year: 2016 🧠🩻

  • The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power – Cited by: 58 – Year: 2018 🧠⚖️

  • New insights in the limbic modulation of visual inputs: The role of the inferior longitudinal fasciculus and the Li-Am bundle – Cited by: 55 – Year: 2014 🧠🔬

  • Awake surgery in low-grade gliomas harboring eloquent areas: 3-year mean follow-up – Cited by: 49 – Year: 2011 🧠💉

  • Time course of neurological deficits after surgery for primary brain tumours – Cited by: 47 – Year: 2020 🧠🕰️

  • Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry – Cited by: 46 – Year: 2014 🧠📈

  • Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson’s disease – Cited by: 46 – Year: 2010 🧠⚖️

  • Is the resection of gliomas in Wernicke’s area reliable? – Cited by: 45 – Year: 2012 🧠💬

  • miRNAs expression analysis in paired fresh/frozen and dissected formalin fixed and paraffin embedded glioblastoma using real-time PCR – Cited by: 39 – Year: 2012 🧠🔬

  • The use of a cerebral perfusion and immersion–fixation process for subsequent white matter dissection – Cited by: 34 – Year: 2015 🧠⚙️

  • Mobilization of the transcavernous oculomotor nerve during basilar aneurysm surgery: biomechanical bases for better outcome – Cited by: 34 – Year: 2014 🧠⚙️

  • New insights into the anatomy, connectivity and clinical implications of the middle longitudinal fasciculus – Cited by: 33 – Year: 2021 🧠🌐

  • Definition of miRNAs expression profile in glioblastoma samples: the relevance of non-neoplastic brain reference – Cited by: 32 – Year: 2013 🧠📚

Beatriz Veiga | Neuroscience | Best Researcher Award

Posted on by ScienceFather

Dr. Beatriz Veiga | Neuroscience | Best Researcher Award

Dr. Beatriz Veiga, Universidade Federal de São Paulo, Brazil

Dr. Beatriz Azevedo dos Anjos Godke Veiga is a Brazilian neurologist with a focus on movement disorders. She completed her medical degree in 2001 at Universidade Estadual de Londrina, followed by a Master’s and Doctorate in Neurology/Neurosciences at Universidade Federal de São Paulo (UNIFESP). Her doctoral research, completed in 2023, examined the association between compulsive behaviors and levodopa-induced dyskinesias in Parkinson’s disease patients. Dr. Veiga is currently a neurologist at Hospital Ipiranga and a faculty member at Universidade Nove de Julho. Her research interests include impulsive behaviors, dyskinesias, and Parkinson’s disease. She has received multiple awards, including the International Congress Travel Grant Award from the Movement Disorders Society in 2019 and 2022. Her published work includes articles on depression in Parkinson’s disease and fatigue in geriatric patients. Dr. Veiga is actively involved in several research projects, particularly those exploring the relationship between early-onset Parkinson’s disease and dopamine agonists.

Publication Profile

Orcid

Awards and Titles 🏆

Dr. Beatriz Veiga has earned significant recognition in the field of movement disorders. In 2022, she was awarded the International Congress Travel Grant Award by the Movement Disorders Society 🌍, highlighting her contributions and research in this specialized area. This prestigious honor was preceded by another International Congress Travel Grant Award in 2019, further solidifying her standing within the international scientific community. Dr. Veiga’s continuous dedication to advancing the understanding of movement disorders has positioned her as a prominent figure in the field, earning accolades for her expertise and commitment to research. 🌟

 

Academic Background 🎓

Dr. Beatriz Veiga’s academic journey has been marked by excellence in the field of Neurology and Neurosciences. She completed her PhD in Neurology/Neurosciences at the Federal University of São Paulo (UNIFESP), Brazil, in 2023, with a thesis on the association between compulsive impulsive behaviors and levodopa-induced dyskinesias in Parkinson’s disease patients 🧠. Dr. Veiga also holds a Master’s degree from UNIFESP (2008), focusing on depression in Parkinson’s disease. Her medical residency in Neurology was completed at the State University of Londrina (UEL), Brazil, where she was a CNPq scholar. She holds a degree in Medicine from UEL (2001). 🎓

 

Complementary Education 📚

Dr. Beatriz Veiga has enhanced her expertise in Neurology through specialized training. In 2019, she completed a short course in Deep Brain Stimulation (DBS) at the International Academy, gaining 25 hours of focused learning on this advanced therapy for movement disorders 🧠. She also participated in an Observership program at the Movement Disorders Clinic, University of Toronto, with a focus on DBS, accumulating 160 hours of hands-on experience. Dr. Veiga is a Neurologist and Preceptor at Hospital Ipiranga, and a faculty member at the University of Nove de Julho, specializing in movement disorders. 💡

 

Professional Experience 🏥

Dr. Beatriz Veiga has extensive professional experience in Neurology and academia. Since 2008, she has been a Full Member of the Academia Brasileira de Neurologia (ABN). She is also an active member of the Movement Disorder Society (MDS) since 2017. Dr. Veiga is a Faculty Member at the University of Nove de Julho (UNINOVE) since 2012, where she teaches in the Medicine program 🩺. Additionally, she has served as a Neurologist and Preceptor at Hospital Ipiranga since 2010, training the next generation of neurologists. Her expertise has been pivotal in the field of movement disorders. 🌟

 

Research Focus

Dr. Beatriz A. Anjos G. Veiga’s research primarily focuses on neurology and movement disorders, specifically the relationship between impulsive-compulsive behaviors (ICBs) and Levodopa-induced dyskinesia (LID) in Parkinson’s disease. Her work, demonstrated in the study “Are Impulsive Compulsive Behaviors Associated with Levodopa-Induced Dyskinesia?”, explores how these behaviors contribute to the clinical presentation of Parkinson’s disease and its treatment. She investigates the neurophysiological mechanisms behind these effects, aiming to improve therapeutic strategies. Her research contributes significantly to understanding the cognitive and motor complications of Parkinson’s disease and optimizing management strategies. 🩺🔬

 

Publication Top Notes

Are Impulsive Compulsive Behaviors Associated with Levodopa-Induced Dyskinesia? A Brazilian Cross-Sectional Study

Gaiqing Wang | Neurodegeneration Disease | Research and Development Excellence Award

Posted on by ScienceFather

Prof. Gaiqing Wang | Neurodegeneration Disease | Research and Development Excellence Award

Prof. Gaiqing Wang, Sanya Central Hospital (The Third People’s Hospital of Hainan Province), China

Prof. Gaiqing Wang is a distinguished neurologist affiliated with Sanya Central Hospital, Hainan Province, specializing in cerebrovascular diseases. Holding a Ph.D. from Central South University, he focuses on cerebral small vessel disease and endogenous waste clearance in the brain. With over 70 publications, including 27 SCI-indexed papers, Prof. Wang investigates mechanisms of intracerebral hemorrhage and neurodegenerative disorders. He leads numerous research projects funded by national and provincial bodies, exploring innovative therapeutic approaches. His contributions extend to consultancy, industry projects, and authoring books and patents. A member of prestigious professional societies, his work bridges neuroscience research with clinical applications 🧠🔬.

Publication profile

Orcid

Academic and Professional Background 🎓

Gaiqing Wang, currently serving as a Professor at Sanya Central Hospital, earned a Ph.D. in Neurology from Central South University in 2006. Specializing in cerebral small vessel disease and brain waste clearance mechanisms, Wang has authored over 70 papers and secured funding for 13 research projects. His impactful contributions include elucidating the role of microglia in hematoma clearance post-intracerebral hemorrhage and exploring circadian regulation of brain clearance systems. Wang’s academic prowess is underscored by leadership in consultancy projects and publication of several books and patents, consolidating his standing as a distinguished figure in neurological research.

Research Focus

Gaiqing Wang primarily focuses on neuroinflammation and neuroprotection in various neurological disorders, prominently in conditions like Alzheimer’s disease, intracerebral hemorrhage, and subarachnoid hemorrhage. His research explores mechanisms involving oxidative stress, microglial activation, and therapeutic interventions such as dexmedetomidine and PPAR-γ agonists. Wang’s work spans across multiple facets of brain injury and repair, emphasizing the roles of microglia, astrocytes, and clearance systems in these pathological processes. His contributions highlight the intricate signaling pathways and potential therapeutic targets 🧠🔬, advancing understanding and treatment strategies for severe neurological conditions.

Publication Top Notes

Dexmedetomidine mitigates neuroinflammation in an Alzheimer’s disease mouse model via the miR-204-3p/FBXL7 signaling axis

Published in Brain Research (2024)
Year of Publication: 2024 🧠
Neuroprotection by Nrf2 via modulating microglial phenotype and phagocytosis after intracerebral hemorrhage

Published in Heliyon (2023)
Year of Publication: 2023 🧠
Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders

Published in Neurobiology of Disease (2023)
Year of Publication: 2023 🧠
Clearance Systems in the Brain, From Structure to Function

Published in Frontiers in Cellular Neuroscience (2022)
Year of Publication: 2022 🧠
Editorial: Brain injury and repair following cerebrovascular diseases: From bench to bedside

Published in Frontiers in Cellular Neuroscience (2022)
Year of Publication: 2022 🧠

Linjing Mu | Brain PET Imaging Award | Best Researcher Award

Posted on by ScienceFather

Dr. Linjing Mu | Brain PET Imaging Award | Best Researcher Award

Dr. Linjing Mu, ETH Zurich, Switzerland

🔬 Dr. Linjing Mu pursued doctoral research at Nankai University, followed by a post-doctoral fellowship at Basel University, Switzerland. With expertise in radiopharmaceutical sciences, Dr. Mu led research teams at University Hospital Zurich and ETH Zurich, focusing on lead structure discovery, ligand synthesis, and radiolabeling method development. A prolific author, Dr. Mu has 106 peer-reviewed publications, including 10 as last and corresponding author, and 19 as the first author. Co-investigator on 10 patents, Dr. Mu has presented internationally and collaborated with industry leaders like Bayer Schering, Novartis, and Roche, contributing significantly to drug discovery and clinical translations.

 

Publication Profile:

Scopus

Orcid

Education:

Doctoral Research in Chemistry Department, Nankai University (1993-1996)

Post-Doctoral Fellow, Basel University, Switzerland (1996-2001)

Experience:

Team Leader in the field of Radiopharmaceutical Sciences, Group of Prof. Schubiger (2001-2010)

Head of Research, Radiopharmacy, University Hospital Zurich (2010-2021)

Senior Scientist, Prof. Schibli’s Group, ETH Zurich (2021-Present)

Research Expertise:

Lead Structure Finding based on Literature and Patents

Design and Synthesis of Novel Ligands

Structure-Activity Relationship Studies

Radiolabeling Method Development

In Vitro and In Vivo Evaluation

Academic Achievements:

Co-authored 106 Peer-Reviewed Publications

Last and Corresponding Author on 10, First Author on 19 (H-Factor 29, Scopus)

Co-Investigator on 10 Patent Applications

Contributed to International Conferences as Invited Speaker, Oral and Poster Presenter

Research Focus:

🔬 Dr. Linjing Mu’s research focus lies at the intersection of neuroimaging and drug development, particularly in the field of molecular imaging for neurodegenerative diseases like Alzheimer’s. Their work encompasses the development and optimization of radioligands targeting specific molecular pathways implicated in neurodegeneration. Through PET/MRI studies and the exploration of novel PET tracers, such as (R)-[18F]YH134 and (R)-[18F]PSS232, Dr. Mu aims to deepen our understanding of disease mechanisms and identify potential therapeutic targets. This research not only sheds light on disease pathology but also paves the way for the development of new diagnostic tools and pharmacological interventions.

 

Publication Top Notes:

📄 Wang, J. et al. Metabotropic glutamate receptor 5 (mGluR5) is associated with neurodegeneration and amyloid deposition in Alzheimer’s disease: A [18F]PSS232 PET/MRI study. Published in Alzheimer’s Research and Therapy, 2024. Cited by: 0.

📄 He, Y. et al. Identification of (R)-[18F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development. Published in Journal of Nuclear Medicine, 2024. Cited by: 0.

📄 Boccalini, C. et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Published in Alzheimer’s and Dementia, 2024. Cited by: 1.

📄 Trachsel, B. et al. Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK. Published in EJNMMI Radiopharmacy and Chemistry, 2023. Cited by: 0.

📄 Lu, Y. et al. Proof-of-concept optimization of a copper-mediated 18F-radiosynthesis of a novel MAGL PET tracer on a high-throughput microdroplet platform and its macroscale translation. Published in Lab on a Chip, 2023. Cited by: 1.

📄 Ni, R. et al. Imaging increased metabolism in the spinal cord in mice after middle cerebral artery occlusion. Published in Photoacoustics, 2023. Cited by: 0.

📄 Zechner, M. et al. In Vitro and In Vivo Evaluation of ABCG2 (BCRP) Inhibitors Derived from Ko143. Published in Journal of Medicinal Chemistry, 2023. Cited by: 1.

📄 Bengs, S. et al. Rest/stress myocardial perfusion imaging by positron emission tomography with 18F-Flurpiridaz: A feasibility study in mice. Published in Journal of Nuclear Cardiology, 2023. Cited by: 3.

📄 Peretti, D.E. et al. ATN profile classification across two independent prospective cohorts. Published in Frontiers in Medicine, 2023. Cited by: 0.

📄 He, Y. et al. Multi-parameter optimization: Development of a morpholin-3-one derivative with an improved kinetic profile for imaging monoacylglycerol lipase in the brain. Published in European Journal of Medicinal Chemistry, 2022. Cited by: 2.